Journal article
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate
Abstract
PURPOSE: Gene fusions leading to androgen receptor-modulated ERG overexpression occur in up to 70% of metastatic castration-resistant prostate cancers (mCRPC). We assessed the association between ERG rearrangement status and clinical benefit from abiraterone acetate.
EXPERIMENTAL DESIGN: COU-AA-302 is a phase III trial comparing abiraterone acetate and prednisone versus prednisone in chemotherapy-naïve mCRPC. ERG status was evaluated by FISH on …
Authors
Attard G; de Bono JS; Logothetis CJ; Fizazi K; Mukherjee SD; Joshua AM; Schrijvers D; van den Eertwegh AJM; Li W; Molina A
Journal
Clinical Cancer Research, Vol. 21, No. 7, pp. 1621–1627
Publisher
American Association for Cancer Research (AACR)
Publication Date
April 1, 2015
DOI
10.1158/1078-0432.ccr-14-1961
ISSN
1078-0432